IPO News & Commentary
Get the latest insights on new stocks
- Metal powder producer Amaero prices downsized US IPO at $4.25 per share 10/14/26
- Tungsten Miners Weigh IPOs Following Price Surge 10/14/26
- Cardiac medical device developer BioVentrix withdraws $17 million IPO 10/14/26
- Biotech-focused SPAC Frazier Life Sciences Acquisition II prices $75 million IPO 10/14/26
- IPO Weekly Weigh-in: Why investors said no to this $3.5B AI IPO 10/14/26
- SPAC Hall Chadwick Acquisition II lowers deal size by 25% ahead of $200 million IPO 10/13/26
- SPAC EuroSPAC Acquisition files for a $125 million US IPO, led by the CEO of Euroseas 10/13/26
See more
IPO News By Industry
- Christian-focused connectivity firm Patriot Mobile files for a $10 million IPO 10/09/26
- Hong Kong-based marketing firm AM PM Group doubles shares offered ahead of $34 million US IPO 08/27/26
- Hong Kong digital marketing provider Poche Technology ups range to $5 to $7 ahead of $38 million US IPO 08/06/26
NYSE IPO News
- IPO Weekly Weigh-in: Why investors said no to this $3.5B AI IPO 10/14/26
- Emerging markets fintech OPay files for an estimated $500 million US IPO 10/09/26
- Cavity treatment provider vVardis files for an estimated $200 million US IPO 10/09/26
- SPAC Calm Seas Acquisition lowers units offered by 25% ahead of $200 million IPO 10/08/26
- Spinal implant developer Centinel Spine files for a $100 million IPO 10/07/26
Nasdaq IPO News
- SPAC TCGX Acquisition II prices $100 million IPO, targeting healthcare in Asia 10/16/26
- City Therapeutics prices upsized IPO at $18, the midpoint of the range 10/16/26
- Small molecule biotech Iambic Therapeutics prices IPO at $16, the midpoint of the range 10/15/26
- Metal powder producer Amaero prices downsized US IPO at $4.25 per share 10/14/26
- Cardiac medical device developer BioVentrix withdraws $17 million IPO 10/14/26
Be the in-house IPO Expert
Our clients are focused on catalyzing growth and creating value.
Not scouring the web for IPO data.
Get the information you need in minutes, not hours. With IPO Pro, you have the entire US IPO market at your fingertips.
SPAC TCGX Acquisition II prices $100 million IPO, targeting healthcare in Asia
TCGX Acquisition II, a blank check company formed by TCGX executives targeting healthcare in Asia, raised $100 million by offering 10 million shares at $10. Unlike most SPACs, the offering did not contain units with warrants or rights attached. TCGX...read more
City Therapeutics prices upsized IPO at $18, the midpoint of the range
City Therapeutics, a Phase 1 biotech developing RNA interference therapies for thromboembolic diseases, raised $200 million by offering 11.1 million shares at $18, within the $17 to $19 range. At pricing, the company commands a fully diluted market value of...read more
Small molecule biotech Iambic Therapeutics prices IPO at $16, the midpoint of the range
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, raised $150 million by offering 9.4 million shares at $16, within the $15 to $17 range. Existing shareholder ARK Investment Management and new investor...read more